Cel-Sci Corp. (CVM)

Overview News Price History Option Chain Discussions Forecast Stock Split Dividend History

Cel-Sci Corp. stock is currently priced at $1.52, with a 24-hour trading volume of 23,568. It has seen a +1.33% increased in the last 24 hours and a -25.12% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.54 pivot point. If it approaches the $1.46 support level, significant changes may occur.

Cel-Sci Corp. Stock (CVM) Financials Data

Cel-Sci Corp. (CVM) Net Income 2024

CVM net income (TTM) was -$32.37 million for the quarter ending September 30, 2023, a +11.81% increase year-over-year.

Cel-Sci Corp. (CVM) Cash Flow 2024

CVM recorded a free cash flow (TTM) of -$23.22 million for the quarter ending September 30, 2023, a -22.85% decrease year-over-year.

Cel-Sci Corp. (CVM) Earnings per Share 2024

CVM earnings per share (TTM) was -$0.72 for the quarter ending September 30, 2023, a +17.24% growth year-over-year.

Cel-Sci Corp. Stock (CVM) Latest News

Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.